mouse anti alpha smooth muscle actin  (Santa Cruz Biotechnology)

Journal: bioRxiv

Article Title: A Biphasic Effect of Alcohol on Endothelial Plasticity Through Regulation of Endothelial-to-Mesenchymal Transition

doi: 10.64898/2026.04.14.718463

Figure Lengend Snippet: (a-c) SM22α, eNOS, αSMA, and Fibronectin (FN) mRNA levels determined by qRT-PCR in human coronary artery endothelial cells (HCAEC) following treatment with TGFβ1 (10 ng/ml, 7d), hypoxia (5% O 2 , 4d) or TGFβ1 plus hypoxia (4d), in the absence or presence of ethanol (EtOH) at concentrations indicated (0-100 mM range). (d) SM22α, eNOS, and Cdh5 mRNA levels in HCAEC treated with TGFβ1 (10 mg/ml, 2d) +/- EtOH 25 mM or 100 mM. (e) Representative western blots showing CD31, Cdh5, SM22α, and SNAIL protein expression in HCAEC treated with TGFβ1, IL-1β, or Hypoxia +/- EtOH (25 mM or 100 mM). β-actin or GAPDH were used as loading controls. Data are mean±SEM, n=3. *p<0.05 vs control (no treatment), #p<0.05 vs TGFβ1 or hypoxia.

Article Snippet: Primary antibodies used include human CD31 (Cat. # AF806, R&D Systems), αSMA (MAB1420, R&D systems), SM22α (Cat. # 36090 CST), and CDH5 (Cat. # 2500, CST).

Techniques: Quantitative RT-PCR, Western Blot, Expressing, Control

Journal: bioRxiv

Article Title: A Biphasic Effect of Alcohol on Endothelial Plasticity Through Regulation of Endothelial-to-Mesenchymal Transition

doi: 10.64898/2026.04.14.718463

Figure Lengend Snippet: (a) CD31 expression in HCAEC treated with TGFβ1 (10ng/ml), Hypoxia (5% O 2 ), or TGFβ1+ Hypoxia in the absence or presence of moderate dose ethanol (EtOH 25 mM). (b) αSMA expression in HCAEC treated with TGFβ +/- either moderate dose ethanol (25 mM EtOH) or high dose ethanol (100 mM EtOH). (c) SM22α and (d) αSMA expression in HUVEC treated with IL1β+TGFβ2 in the absence or presence of either 25 mM EtOH or 100 mM EtOH as indicated. Representative immunofluorescence images, from at least 3 experiments, shown.

Article Snippet: Primary antibodies used include human CD31 (Cat. # AF806, R&D Systems), αSMA (MAB1420, R&D systems), SM22α (Cat. # 36090 CST), and CDH5 (Cat. # 2500, CST).

Techniques: Expressing, Immunofluorescence

Journal: bioRxiv

Article Title: A Biphasic Effect of Alcohol on Endothelial Plasticity Through Regulation of Endothelial-to-Mesenchymal Transition

doi: 10.64898/2026.04.14.718463

Figure Lengend Snippet: (a) (b) Representative images of immunofluorescently stained carotid cross sections from sham-operated and ligated controls, moderate EtOH, and Binge EtOH experimental groups (males). Blue = Dapi nuclear stain, red = Tm-Cdh5+, and white=αSMA+. (c) Cells co-expressing Cdh5 and αSMA (i.e., myo-endothelial cells indicative of EndMT) were quantified using QuPath bioimage analysis software in carotid cross sections post-ligation from controls (grey bars), moderate EtOH (green bars), and binge EtOH (red bars) experimental groups. Bar graphs show cumulative data expressed as % Myoendothelial cells /full cross section, % Myoendothelial cells /neointima, or Number of myoendothelial cells/full cross section. Data are mean±SEM, n=25-30 sections from 5-6 mice). *p<0.05, ** P<0.001, **** p<0.0001.

Article Snippet: Primary antibodies used include human CD31 (Cat. # AF806, R&D Systems), αSMA (MAB1420, R&D systems), SM22α (Cat. # 36090 CST), and CDH5 (Cat. # 2500, CST).

Techniques: Staining, Expressing, Software, Ligation

Journal: Endoscopy International Open

Article Title: Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study

doi: 10.1055/a-2820-3721

Figure Lengend Snippet: Histopathologic evaluation of ulcer healing. a Thickness of granulation tissue and representative images of Azan-Mallory staining in the rebamipide and control groups on POD 7 (Scale bar, 1000 µm). The rebamipide group exhibited a greater thickness of granulation tissue compared with the control group (718.0 ± 144.0 µm vs. 589.6 ± 84.9 µm), although this difference did not reach statistical significance (P = 0.12). b The number of microvessels and representative images of α-SMA sections in the rebamipide and control groups on POD 7 (Scale bar, 50 µm). Although the rebamipide group showed a greater number of microvessels (17.0 ± 3.4 vs. 13.8 ± 1.5), the difference was not statistically significant (P = 0.10). c Widths of absent muscularis mucosae and representative images of Azan Mallory staining in the rebamipide and control groups on PODs 7, 14 and 21 (Scale bar, 2500 µm for POD 7; 1000 µm for PODs 14 and 21). Mean widths in the rebamipide and control groups on PODs 7, 14, and 21 were 13.8 ± 2.8 ×10³/µm vs. 13.9 ± 2.2 ×10³/µm (P = 0.93), 4.0 ± 1.7 ×10³/µm vs. 5.3 ± 1.9 ×10³/µm (P = 0.33), and 2.3 ± 1.6 ×10³/µm vs. 3.5 ± 2.2 ×10³/µm (P = 0.37), respectively. Although widths tended to be shorter in the rebamipide group on PODs 14 and 21, no statistically significant differences were detected. Linear mixed‑effects analysis revealed no significant group-time interaction. α-SMA, α-smooth muscle actin; POD, postoperative day.

Article Snippet: Serial sections were cut for immunostaining using the mouse monoclonal anti-α-smooth muscle actin (α-SMA) antibody (1:400 dilution, 1A4/asm-1; Novus Biologicals, Littleton, Colorado, United States).

Techniques: Staining, Control

Journal: Endoscopy International Open

Article Title: Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study

doi: 10.1055/a-2820-3721

Figure Lengend Snippet: Histopathologic evaluation of fibrosis formation. a Proportion of α-SMA-positive cells and representative images of α-SMA sections in the rebamipide and control groups on PODs 7, 14, and 21 (Scale bar, 50 µm). Proportions of α‑SMA–positive cells in the rebamipide and control groups on PODs 7, 14, and 21 were 29.0 ± 9.1% vs. 35.1 ± 9.0% (P = 0.22), 24.3 ± 7.9% vs. 27.4 ± 7.5% (P = 0.52), and 19.2 ± 2.2% vs. 25.8 ± 7.4% (P = 0.18), respectively ( a ). Although none of these differences were statistically significant, the rebamipide group consistently showed lower proportions of α‑SMA–positive cells across all time points. Linear mixed‑effects analysis revealed no significant group–time interaction. b Thickness of fibrosis and representative images of Azan-Mallory staining in the rebamipide and control groups on PODs 7, 14, and 21 (Scale bar, 500 µm). Thickness of fibrosis in the rebamipide and control groups on PODs 7, 14, and 21 was 558.6 ± 169.7 µm vs. 450.8 ± 131.1 µm (P = 0.58), 807.0 ± 238.9 µm vs. 972.8 ± 395.1 µm (P = 0.40), and 782.8 ± 281.5 µm vs. 1087.0 ± 476.0 µm (P = 0.13), respectively. Fibrosis progressed on POD 7 but was attenuated on PODs 14 and 21 in the rebamipide group compared with the control group. Linear mixed‑effects analysis demonstrated a significant group–time interaction, with the between‑group difference becoming evident at POD 21 (P = 0.049). α-SMA, α-smooth muscle actin; POD, postoperative day

Article Snippet: Serial sections were cut for immunostaining using the mouse monoclonal anti-α-smooth muscle actin (α-SMA) antibody (1:400 dilution, 1A4/asm-1; Novus Biologicals, Littleton, Colorado, United States).

Techniques: Control, Staining